Advertisement

Instant Oncology: SCOT

Published:August 28, 2021DOI:https://doi.org/10.1016/j.clon.2021.08.007
      The author declares no conflict of interest.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Clinical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Iveson T.J.
        • Kerr R.S.
        • Saunders M.P.
        • Cassidy J.
        • Hollander N.H.
        • Tabernero J.
        • et al.
        3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
        Lancet Oncol. 2018; 19: 562-578
        • André T.
        • Meyerhardt J.
        • Iveson T.
        • Sobrero A.
        • Yoshino T.
        • Souglakos I.
        • et al.
        Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
        Lancet Oncol. 2020; 21: 1620-1629
        • André T.
        • Boni C.
        • Mounedji-Boudiaf L.
        • Navarro M.
        • Tabernero J.
        • Hickish T.
        • et al.
        Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
        N Engl J Med. 2004; 350: 2343-2351
        • Cancer Research UK
        Bowel Cancer Statistics.
        • Robles-Zurita J.
        • Boyd K.A.
        • Briggs A.H.
        • Iveson T.
        • Kerr R.S.
        • Saunders M.P.
        • et al.
        SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
        Br J Cancer. 2018; 119: 1332-1338
        • Chionh F.
        • Lau D.
        • Yeung Y.
        • Price T.
        • Tebbutt N.
        Oral versus intravenous fluoropyrimidines for colorectal cancer.
        Cochrane Database Syst Rev. 2017; 7CD008398